Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials

por Vogt, Liffert, Bangalore, Sripal, Fayyad, Rana, Melamed, Shari, Hovingh, G. Kees, DeMicco, David A., Waters, David D.
Publicado en J Am Heart Assoc (2019)

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin

por Ong, Kwok Leung, Waters, David D., Fayyad, Rana, Vogt, Liffert, Melamed, Shari, DeMicco, David A., Rye, Kerry‐Anne, Barter, Philip J.
Publicado en J Am Heart Assoc (2018)

Determinants of Residual Risk in Secondary Prevention Patients Treated with High-Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study

por Mora, Samia, Wenger, Nanette K., DeMicco, David A., Breazna, Andrei, Boekholdt, S. Matthijs, Arsenault, Benoit J., Deedwania, Prakash, Kastelein, John J.P., Waters, David D.
Publicado 2012

Relationship between atorvastatin dose and the harm caused by torcetrapib

por Barter, Philip J., Rye, Kerry-Anne, Beltangady, Mohan S., Ports, William C., Duggan, William T., Boekholdt, S. Matthijs, DeMicco, David A., Kastelein, John J. P., Shear, Charles L.
Publicado 2012

Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study)

por Ho, Jennifer E., Waters, David D., Kean, Allison, Wilson, Daniel J., DeMicco, David A., Breazna, Andrei, Wun, Chuan-Chuan, Deedwania, Prakash C., Khush, Kiran K.
Publicado en Am J Cardiol (2012)

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Ana...

por Colhoun, Helen M., Betteridge, D. John, Durrington, Paul, Hitman, Graham, Neil, Andrew, Livingstone, Shona, Charlton-Menys, Valentine, Bao, Weihang, DeMicco, David A., Preston, Gregory M., Deshmukh, Harshal, Tan, Kathryn, Fuller, John H.
Publicado 2011

Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers

por Arsenault, Benoit J., Barter, Philip, DeMicco, David A., Bao, Weihang, Preston, Gregory M., LaRosa, John C., Grundy, Scott M., Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K., Shepherd, James, Waters, David D., Kastelein, John J. P.
Publicado en PLoS One (2014)

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

por Soedamah-Muthu, Sabita S., Livingstone, Shona J., Charlton-Menys, Valentine, Betteridge, D. John, Hitman, Graham A., Neil, H. Andrew W., Bao, Weihang, DeMicco, David A., Preston, Gregory M., Fuller, John H., Stehouwer, Coen D. A., Schalkwijk, Casper G., Durrington, Paul N., Colhoun, Helen M.
Publicado en Diabetologia (2015)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

por Deshmukh, Harshal A., Colhoun, Helen M., Johnson, Toby, McKeigue, Paul M., Betteridge, D. John, Durrington, Paul N., Fuller, John H., Livingstone, Shona, Charlton-Menys, Valentine, Neil, Andrew, Poulter, Neil, Sever, Peter, Shields, Denis C., Stanton, Alice V., Chatterjee, Aurobindo, Hyde, Craig, Calle, Roberto A., DeMicco, David A., Trompet, Stella, Postmus, Iris, Ford, Ian, Jukema, J. Wouter, Caulfield, Mark, Hitman, Graham A.
Publicado 2012

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients; a meta-analysis

por Boekholdt, S. Matthijs, Arsenault, Benoit J., Hovingh, G. Kees, Mora, Samia, Pedersen, Terje R., LaRosa, John C., Welch, K.M.A., Amarenco, Pierre, DeMicco, David A., Tonkin, Andrew M., Sullivan, David R., Kirby, Adrienne, Colhoun, Helen M., Hitman, Graham A., Betteridge, D. John, Durrington, Paul N., Clearfield, Michael B., Downs, John R., Gotto, Antonio M., Ridker, Paul M., Kastelein, John J.P.
Publicado 2013

Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials

por Boekholdt, S. Matthijs, Hovingh, G. Kees, Mora, Samia, Arsenault, Benoit J., Amarenco, Pierre, Pedersen, Terje R., LaRosa, John C., Waters, David D., DeMicco, David A., Simes, R. John, Keech, Antony C., Colquhoun, David, Hitman, Graham A., Betteridge, D. John, Clearfield, Michael B., Downs, John R., Colhoun, Helen M., Gotto, Antonio M., Ridker, Paul M., Grundy, Scott M., Kastelein, John J.P.
Publicado en J Am Coll Cardiol (2014)